2
|
Santella JB, Gardner DS, Duncia JV, Wu H, Dhar M, Cavallaro C, Tebben AJ, Carter PH, Barrish JC, Yarde M, Briceno SW, Cvijic ME, Grafstrom RR, Liu R, Patel SR, Watson AJ, Yang G, Rose AV, Vickery RD, Caceres-Cortes J, Caporuscio C, Camac DM, Khan JA, An Y, Foster WR, Davies P, Hynes J. Discovery of the CCR1 Antagonist, BMS-817399, for the Treatment of Rheumatoid Arthritis. J Med Chem 2014; 57:7550-64. [DOI: 10.1021/jm5003167] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Joseph B. Santella
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Daniel S. Gardner
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - John V. Duncia
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Hong Wu
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Murali Dhar
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Cullen Cavallaro
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Andrew J. Tebben
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Percy H. Carter
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Joel C. Barrish
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Melissa Yarde
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Stephanie W. Briceno
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Mary Ellen Cvijic
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - R. Robert Grafstrom
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Richard Liu
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Sima R. Patel
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Andrew J. Watson
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Guchen Yang
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Anne V. Rose
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Rodney D. Vickery
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Janet Caceres-Cortes
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Christian Caporuscio
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Daniel M. Camac
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Javed A. Khan
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Yongmi An
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - William R. Foster
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Paul Davies
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - John Hynes
- Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
3
|
Gardner DS, Santella JB, Duncia JV, Carter PH, Dhar T, Wu H, Guo W, Cavallaro C, Van Kirk K, Yarde M, Briceno SW, Robert Grafstrom R, Liu R, Patel SR, Tebben AJ, Camac D, Khan J, Watson A, Yang G, Rose A, Foster WR, Cvijic ME, Davies P, Hynes J. The discovery of BMS-457, a potent and selective CCR1 antagonist. Bioorg Med Chem Lett 2013; 23:3833-40. [DOI: 10.1016/j.bmcl.2013.04.079] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2013] [Revised: 04/24/2013] [Accepted: 04/29/2013] [Indexed: 02/07/2023]
|
4
|
Abstract
The chemokine receptor CCR1 has been the target of intensive research for nearly two decades. Small-molecule antagonists were first reported in 1998 and, since then, many inhibitors for CCR1 have been brought forth. Yet, with all the money and time spent, to date, no small-molecule antagonists have successfully moved past Phase II clinical trials. With the current advancement of CCR1 antagonists by Bristol-Myers Squibb and Chemocentrix, there has been renewed interest. In this review, we present an overview of CCR1, its activating ligands, methods of signaling, and downstream response. We discuss studies that indicate CCR1 plays an important role in multiple myeloma and the underlying molecular mechanisms. Finally, we present an overview of the clinical and preclinical compounds for CCR1. We address individual structures, discuss their pharmacological précis, and summarize the published evidence to assess their value for use in multiple myeloma.
Collapse
|